[Dose-response relationship of intravenous administration of benzquinamide hydrochloride for suppression of cytostatic-induced emesis].
Benzquinamide-HCl (Promecon), a new antiemetic agent, was applied as an intravenous infusion in different doses for prevention of cancer chemotherapy-induced vomiting to 108 patients. All the patients chosen for this trial were treated with regimens containing cisplatin and/or doxorubicin. An antiemetic effect in 70% or more of the cases was noted in doses of 300-500 mg benzquinamide-HCl per day. In conclusion, doses less than this range will not be successful for prevention of vomiting caused by cytotoxic drugs with a high emetic action.
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002945:Cisplatin / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000009:adverse effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011807:Quinolizines / Q000627:therapeutic use*; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control*
D000970:Antineoplastic Agents; D011807:Quinolizines; C100234:benzquinamide; D004317:Doxorubicin; D002945:Cisplatin
Dosis-Wirkungs-Beziehung von intravenös appliziertem Benzquinamidhydrochlorid zur Unterdrückung von Zytostatika-induziertem Erbrechen.